CONCORDBIO2024-01-012024-03-31 CONCORDBIO2024-01-012024-03-31 CONCORDBIO2024-01-012024-03-31in-bse-fin:OneOperatingExpenses01Member CONCORDBIO2024-01-012024-03-31in-bse-fin:FourOperatingExpenses01Member CONCORDBIO2024-03-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543960 CONCORDBIO NA Concord Biotech Limited Equity 2023-04-01 2024-03-31 2024-05-23 2024-05-15 INR Lakhs Yearly 12:45:00 15:00:00 2024-05-23 2024-05-23 true Cash Flow Indirect Declaration of unmodified opinion Single segment Pharmaceuticals 2024-01-01 2024-03-31 Audited Consolidated 3189694000.00 108116000.00 3297810000.00 556681000.00 114500000.00 217258000.00 339554000.00 4628000.00 137180000.00 618822000.00 1988623000.00 1309187000.00 0.00 1309187000.00 299787000.00 37256000.00 337043000.00 0.00 972144000.00 0.00 0.00 0.00 -21981000.00 950163000.00 3963000.00 954126000.00 950163000.00 3963000.00 0.00 104616000.00 1 9.08 9.08 0.00 0.00 9.08 9.08 Notes to the statement of consolidated financial results for the quarter and year ended March 31, 2024 : 1. The Company's equity shares have been listed on National Stock Exchange ( NSE ) and on BSE Limited ( BSE ) on August 18, 2023, by completing Initial Public Offering through offer for sale of 2,09,25,652 equity shares of face value of Rs. 1 each at an issue price of Rs. 741 per equity share by selling shareholder. 2. The above consolidated financial results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on May 23, 2024. The Statutory Auditors have issued audit report on the above results. 3. The total initial public offer expenses are entirely allocated to the selling shareholders except for the listing fees which has been solely borne by the Company. 4. The consolidated financial results for the quarter ended March 31, 2023 have not been subject to limited review or audit. However, the management has exercised necessary diligence to ensure that the financial results for this period provide a true and fair view of the Company's affairs. 5. The figures for the quarter ended March 31, 2024 are the balancing figures between the audited figures with respect to the full financial year and the published unaudited year to date figures upto the third quarter ended December 31, 2023 which were subjected to limited review. 6. The Company and its joint venture are engaged in the business of manufacturing and trading in pharmaceutical products. The entire business is considered as a single operating segment in terms of Indian Accounting Standard (Ind AS) 108 - Operating Segments . 7. The board of directors have recommended dividend of Rs. 8.75/- per fully paid up equity share of Rs. 1/- each for financial year ended March 31, 2024 on outstanding paid up share capital of the company as on date, in its board meeting held on May 23, 2024, subject to approval of shareholders at ensuing annual general meeting of the company. Single segment 2023-04-01 2024-03-31 Audited Consolidated 10169392000.00 337800000.00 10507192000.00 1845371000.00 567389000.00 -120779000.00 1230467000.00 25519000.00 535915000.00 2331373000.00 6415255000.00 4091937000.00 0.00 4091937000.00 998339000.00 46279000.00 1044618000.00 0.00 3047319000.00 0.00 0.00 0.00 33713000.00 3081032000.00 -73000.00 3080959000.00 3081032000.00 -73000.00 0.00 104616000.00 1 15161839000.00 29.45 29.45 0.00 0.00 29.45 29.45 Other Expenses 618822000.00 Other Expenses 2331373000.00 5717327000.00 2114824000.00 0.00 0.00 35831000.00 0.00 0.00 20586000.00 0.00 0.00 0.00 49695000.00 49695000.00 26712000.00 79799000.00 8044774000.00 2079538000.00 2437019000.00 3496089000.00 151421000.00 318823000.00 0.00 194488000.00 6597840000.00 0.00 284933000.00 8962311000.00 0.00 0.00 17007085000.00 104616000.00 15161839000.00 15266455000.00 15266455000.00 0.00 0.00 18870000.00 18870000.00 19561000.00 280645000.00 319076000.00 62298000.00 944353000.00 258271000.00 1264922000.00 62675000.00 39019000.00 54938000.00 0.00 1421554000.00 0.00 0.00 1740630000.00 17007085000.00 25519000.00 43609000.00 -786596000.00 0.00 -45623000.00 0.00 0.00 48952000.00 0.00 -112866000.00 0.00 25008000.00 0.00 535915000.00 0.00 -20583000.00 0.00 36301000.00 0.00 22254000.00 0.00 30411000.00 0.00 -106133000.00 0.00 -34633000.00 0.00 6313000.00 0.00 -392974000.00 3698963000.00 0.00 0.00 0.00 1033496000.00 -10796000.00 2654671000.00 0.00 0.00 7455174000.00 8381000000.00 0.00 0.00 0.00 0.00 0.00 856885000.00 1751000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 207139000.00 0.00 0.00 0.00 0.00 0.00 0.00 27728000.00 0.00 0.00 0.00 -1546093000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 250058000.00 0.00 19386000.00 714529000.00 22088000.00 0.00 13912000.00 -992149000.00 116429000.00 0.00 116429000.00 34992000.00 151421000.00 3963000.00 -73000.00 0.00 0.00 0.00 0.00